Chronic Spontaneous Urticaria Clinical Trial

A PHASE 3 STUDY OF EFFICACY AND SAFETY OF REMIBRUTINIB IN THE TREATMENT OF CSU IN ADULTS INADEQUATELY CONTROLLED BY H1 ANTIHISTAMINES (REMIX-1)

Sponsor: Novartis

Trial Link: https://clinicaltrials.gov/ct2/show/NCT05030311

Medication: Remibrutinib or placebo (randomised 2:1)

Dosing: To be taken orally twice daily for 52 weeks.

Participants in the placebo arm will be switched to active treatment at week 24

Age: ≥ 18
Gender: All

Compensation: \$60 per visit

Duration: 1 year. There will be monthly visits in total for the entire duration of the trial.

About Remibrutinib: Remibrutinib binds and inhibits Bruton's Tyrosine Kinase (BTK) with high selectivity. BTK inhibition targets the immune response thought to be involved in the activation of urticaria.

 □ CSU inadequately controlled by second generation H1-antihistamines □ Presence of daily itch and hives for ≥6 consecutive weeks prior despite the daily use of second generation H1-antihistamines □ Documentation of CSU duration for ≥ 6 months □ Documentation of hives within 3 months □ Documentation of hives within 3 months □ Clearly defined predominant or sole trigger of their chronic urticaria □ Other diseases with symptoms of urticaria □ Any other skin disease associated with chronic itching □ Cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, haematological disorders, gastrointestinal disease or immunodeficiency □ Uncontrolled disease states, eg. anaphylaxis, asthma or inflammatory bowel disease □ History or current hepatic disease □ Malignancy of any organ system within the past 5 years □ Known history or evidence of ongoing alcohol or drug abuse within the last 6 months 	INCLUSIONS	EXCLUSIONS
	 □ CSU inadequately controlled by second generation H1-antihistamines □ Presence of daily itch and hives for ≥6 consecutive weeks prior despite the daily use of second generation H1-antihistamines □ Documentation of CSU duration for ≥ 6 months 	 □ Clearly defined predominant or sole trigger of their chronic urticaria □ Other diseases with symptoms of urticaria □ Any other skin disease associated with chronic itching □ Cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, haematological disorders, gastrointestinal disease or immunodeficiency □ Uncontrolled disease states, eg. anaphylaxis, asthma or inflammatory bowel disease □ History or current hepatic disease □ Malignancy of any organ system within the past 5 years □ Known history or evidence of ongoing alcohol